NCCAM
This article was originally published in The Tan Sheet
Executive Summary
Results from glucosamine/chondroitin trial in treating osteoarthritis (co-sponsored by National Institute of Arthritis & Musculoskeletal & Skin Diseases) will be available in roughly two years, NCCAM Director Stephen Straus, MD, tells House Appropriations/labor-HHS subcommittee at hearing March 28. No adverse events have been reported to date, he says. In addition, studies on effects of soy for menopause and Chinese herbal combination PC-SPES for prostate cancer are progressing and center's new PubMed database for CAM information is being visited at a promising rate, Straus notes. Subcommittee hearing was first to address NCCAM funding under new Chair Ralph Regula (R-Ohio), who replaced six-year former Chair John Porter (R-Ill.) following his retirement
You may also be interested in...
NCCAM PC-SPES Studies In Limbo After BotanicLab Closes Doors
The National Center for Complementary & Alternative Medicine is evaluating the future of multiple PC-SPES studies it is funding following Brea, Calif.-based BotanicLab's recent announcement it is going out of business
NCCAM PC-SPES Studies In Limbo After BotanicLab Closes Doors
The National Center for Complementary & Alternative Medicine is evaluating the future of multiple PC-SPES studies it is funding following Brea, Calif.-based BotanicLab's recent announcement it is going out of business
NCCAM PC-SPES Studies In Limbo After BotanicLab Closes Doors
The National Center for Complementary & Alternative Medicine is evaluating the future of multiple PC-SPES studies it is funding following Brea, Calif.-based BotanicLab's recent announcement it is going out of business